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Objectives: To evaluate prospective single centre experience of mid-term safety and efficacy
of perventricular device closure of isolated large muscular ventricular septal defect (mVSD)
in high-risk infants.
Background: Surgical closures of large mVSD in infants represent a challenge with signifi-
cant morbidity.
Methods: Between August 2008e2010, perventricular closure was attempted in 24 infants of
6.01  2.37 months age and 4.27  0.56 kg weight under TEE guidance.
Results: The device was successfully deployed in 21/24 infants. Size of mVSD
was 8.42  1.46 mm (6.1e12 mm). Mean procedure time was 28.8  11.7 min. The closure
rate was 84% immediately and 100% at 6 months. Four patients suffered major compli-
cations: 2-died, 1-esophageal perforation, 1-persistent CHB. At 26.23  6.63 months
follow-up two patients were symptomatic: 1-required device retrieval, 1-died of severe
gastroenteritis.
Conclusion: Perventricular device closure of isolated mVSD appears feasible option
at mid-term follow-up and may either substitute or complement the conventional
surgical technique in selected cases depending on institutional paediatric cardiac surgery
performance.
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inability to locate the defect during ventriculotomy and occa-
sionally, by LV dysfunction.4 The percutaneous closure of
mVSD is an alternative technique with encouraging results in
children.8,9 However, its application in infants is limited due to
relatively large size of the device-delivery-apparatus, which
may cause hemodynamic instability and rhythm distur-
bances.10 This underscores the need for a hybrid approach
where the access obtainedby sternotomyor epigastric incision
allows deployment of closure device into the beating-heart
under echocardiographic and/or fluoroscopic guidance. The
short-term results of perventricular VSD device closure as
a sole procedure for isolated VSDs and as an additional
procedure for VSDs in complex congenital heart disease (CHD)
are promising in several,mixed, small cohorts of patients.11e18
We aim to report our experience with perventricular device
closure of isolated large mVSD in a relatively large cohort of
high-risk infants.2. Materials and methods
2.1. Inclusion criteria
Our patient population consists of infants with symptomatic
large mVSD and left to right shunt. The suitability criteria for
perventricular closure of mVSD included: (1) symptoms of
persistent heart failure including failure to thrive despite
optimal medical management, (2) body weight less than 5 kg,
which is considered inappropriately low for standard percu-
taneous closure, (3) isolated large muscular VSD with left to
right shunt and significant pulmonary arterial hypertension
(4) presence of at least 5 mm muscular rim separating the
defect from semilunar valves and atrioventricular valve
tension apparatus and (5) hemodynamically insignificant left
to right shunt from additional mVSD(s), when present.
The patients with the following criteria were considered
unsuitable for the procedure: (1) additional CHD except small
patent ductus arteriosus (PDA) and atrial septal defect (ASD),
(2) any major debilitating illness making the infant unfit for
cardiac surgery.
The hospital ethics committee approved the study
protocol. A written consent was obtained from both the
parents who were informed and explained about the
nature, the advantages and the disadvantages of the
procedure in comparison with open surgical repair using
cardiopulmonary bypass (CPB). The clinical history and
examination, investigational reports, case notes, echocar-
diography reports, procedure-related notes and post-
procedural findings were recorded in the departmental
database.Fig. 1 e Transesophageal echocardiographic four chamber
view of large mid-mVSD.2.2. Anaesthesia and monitoring
Twenty-four infants who met the suitability criteria were
brought to the operating room (#1e18) or cardiac catheteri-
zation laboratory (#19e24) in a post-absorptive state. Stand-
by CPB machine was available for every procedure. The
procedure was performed under general anaesthesia afteradequate pre-oxygenation. The infants were orotracheally
ventilated with pressure-controlled, volume-guaranteed
artificial ventilation. ECG, pulse oximetry, invasive arterial
pressure, central venous pressure, temperature and urine
output were continuously monitored throughout the
procedure.2.3. Perventricular access
The heart was approached through median sternotomy
(n ¼ 23) or minimally invasive subxiphoid incision (n ¼ 3).
Under continuous transesophageal echocardiographic (TEE)
guidance, the optimal site for right ventricular (RV) puncture
was chosen by indenting the RV free wall with forceps-held
cotton gauze. The puncture site was considered optimal, if it
was away from the papillary muscle and remained at an
adequate distance from the septum so as to allow perpen-
dicular access to the defect (Figs. 1 and 2). After securing
purse-string suture with 6-0 polypropylene around the
optimal puncture site, a 20G needle, Jelco (Smith Medical, UK),
was introduced into the RV, perpendicular to the mVSD. A
0.025-inch straight-tipped guide wire, Terumo (Terumo
Corporation: Tokyo, Japan), was introduced through the nee-
dle and maneuvered across the defect into the LV (Fig. 3).
Unfractionated heparin (50 units/kg bolus) was administered
intravenously. The needle was exchanged with a short 5F
sheath (Terumo Corporation: Tokyo, Japan), over the wire. To
avoid injury to RV free wall and inadvertent perforation
during subsequent manipulation, the tip of the sheath was
parked just across the RV puncture and the partially with-
drawn dilator was left inside it, 5e10 mm beyond its tip.
Customized delivery system including puncture needle may
be used as well.19 The 5F sheath was exchanged with a short 8
or 10F sheath (Cordis Corporation; Miami, FL, USA) over 0.038-
inch angled guide wire (Cordis Corporation; Miami, FL, USA).
The sheath was positioned across the defect with its tip in the
LV cavity (Fig. 4).
2.4. Selection of closure device
The defect size was measured in 4-chamber and long axis TEE
views. The larger of the two values was considered for device
Fig. 2 e RV free wall indentation with a forceps tip, away
from the anterior papillary muscle of the TV.
Fig. 4 e An introducer sheath is passed over a dilator and
positioned into the LV cavity.
i n d i a n h e a r t j o u rn a l 6 4 ( 2 0 1 2 ) 5 5 9e5 6 7 561selection. Themuscular device occluder (Cardi-O-Fix, Starway
Medi Tech, Inc., Beijing, China), 1e2 mm larger than the VSD
size and rim extending 7 mm from the central disk on either
side was selected. The Starway Cardi-O-Fix VSD Occluder is
a self-expandable, double disc implantable device made up of
Nitinol wiremesh. The two discs are linked together by a short
connecting waist corresponding to the size of the VSD. In
order to increase its closing ability, the discs and the waist are
filled with polyester fabric. The polyester fabric is securely
sewn to each disc by surgical sutures.2.5. Deployment of device
The device, pre-soaked in blood, was screwed on to the cable
and loaded inside a 6e8F loader. The device was advanced
into the short sheath and the LV disk opened in mid-LV by
gently retracting the sheath over the cable (Fig. 5). The device
was deployed across the defect under continuous TEE guid-
ance conventionally (Fig. 6). TEE imaging in multiple planes
was undertaken to confirm appropriate device placement and
assess residual shunt, if any. In addition, any new valvular
obstruction or regurgitation was also looked for.Fig. 3 e A guide wire manipulated into the LV.2.6. Post-procedural care and follow-up
Post-procedurally; aspirin (5 mg/kg) was given for 12 months.
Oral diuretic (furosemide, 1 mg/kg) was also prescribed for the
first 3e6 months. Relevant clinical and echocardiographic
details (including residual shunt and pulmonary artery (PA)
pressure estimated by tricuspid regurgitation jet velocity)
were obtained during follow-up visits scheduled at 1, 3, 6, 12,
18 and 24 months, post-discharge. Based on the jet width
detected on transthoracic color Doppler study, the residual
shunt was classified as trivial (<1 mm), small (1e2 mm),
moderate (2e4 mm), or large (>4 mm).3. Results
Table 1 summarizes the results of the study.
3.1. Demographics
From August 2008 to August 2010, 24 symptomatic infants
with mVSD detected on TTE, were found suitable for perven-
tricular device closure at our institute. All infants had eitherFig. 5 e The LV disk of the device has been opened.
Fig. 6 e The device deployed across the defect, not
unscrewed from cable.
i n d i a n h e a r t j o u r n a l 6 4 ( 2 0 1 2 ) 5 5 9e5 6 7562persistent failure to thrive or clinical signs of cardiac failure.
Theirmean agewas 6.01 2.37mon (range 2e12mon) and the
mean weight was 4.27  0.56 kg (range 2.7e4.9 kg). All but 3
infants were malnourished. Eighteen infants had grade IIIeIV
protein energy malnutrition (PEM) and 3 infants had grade II
PEM.20
3.2. Pre-procedural echocardiography
The location of the defect was mid-muscular in 12, distal
septal in 5 and anterior muscular septal in 5 patients. Two
infants had posterior septal defect. The mean echocardio-
graphic size of the mVSD was 8.42  1.46 mm (range
6.1e12 mm) in its longest dimension. Fig. 7 shows the scat-
tered diagram of partial linear relationship between VSD size
and defect to device ratio. Two patients had additional small
muscular VSDs and five had PDA. One patient had bicuspid
aortic valve without significant aortic stenosis. Two other
patients had small ostium secundum ASD. One patient hadTable 1 e Clinical, echocardiography and procedural details of
Patient demographics Echocardiography
Patients 24 VSD
location
Mid-mu
distal s
anterior m
posterior
Sex Male 10
Female 14
VSD Size (mm) 8.42  1.46 (6.1
Age (months) 6.01  2.37 (2e12) Preprocedure PA
Pressure (mmHg)
72.05  10.2
Weight (kg) 4.27  0.56 (2.7e4.9) Additional defect Small mVSDs 0
bicuspid AV 01
PEM status Grade IIIeIV: 18
Grade II: 3
Additional
procedure
Balloon coarct
PDA ligation 05
Abbreviations: mVSDemuscular ventricular septal defect; PAe pulmona
atrial septal defect; AV e aortic valve; PEM e protein energy malnutritionundergone successful balloon coarctoplasty, 1 week prior to
the procedure. Prior to device closure, the mean estimated PA
pressure was 72.05  10.20 mmHg. All infants had normal LV
systolic function at presentation. In 5 patients, surgical liga-
tion of associated PDA was accomplished successfully during
perventricular VSD closure.3.3. Acute procedural and echocardiographic outcomes
Successful perventricular device closure was accomplished in
21 out of 24 infants with intention to treat. Three infants,
among the first 18whowere intervened in the operating room,
required surgical closure of the mVSD. The last 6 infants
underwent successful perventricular device closure in the
catheterization laboratory. Excluding the surgical preparation
time, themean procedure timewas 28.8 11.7min. Themean
size of successfully deployed mVSD occluder was
11.5  1.93 mm (range 8e16 mm). Fig. 7 shows the scattered
diagram of partial linear relationship between VSD size and
defect to device ratio. Since the sheaths were gradually
upgraded from smaller to larger size instead of direct use of
large-size sheath, we did not notice any sustained arrhythmia
or mechanical LV compression. Immediately after the mVSD
device closure, 11 infants had no residual shunt; trivial
(intradevice foaming) residual shunt was detected in the
remaining 10. Immediately post-device closure, estimated PA
pressure dropped to mean 56  8.4 mmHg.3.4. Surgical conversion
Three infants failed perventricular device closure of mVSD
and required immediate surgical conversion. One patientwith
mid-mVSD extending into the posterior septum developed
small LV perforation during the introduction of the sheath
over the Terumo wire. In another infant with a similar loca-
tion of mVSD, the defect could not be crossed with the guide
wire even after repeated attempts through different RV
puncture sites. The third infant had a large residual shuntstudy patients.
data Procedure analysis
scular 12,
eptum 05,
uscular 05,
muscular 02
VSD occluder size
Device/defect ratio
11.5  1.93
(8e16 mm)
1.35  0.14
e12) Procedure success Device deployment
21 (complete closure 11,
trivial shunt 10);
surgical closure 03
Post-procedure
PA pressure (mmHg)
56  8.4
2, PDA 05,
, small OS ASD 02
Procedure time
(minutes)
28.8  11
oplasty 01, Median ICCU
stay (days)
3
ry artery; PDAe patent ductus arteriosus; OS ASDe ostium secundum
.
Fig. 7 e Scattered diagram of relationship between VSD size and defect to device size ratio.
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The defect appeared malaligned and was not amenable to
closure with conventionally designed device. Surgical patch
closure was undertaken successfully in all of them.3.5. In-hospital course
The median duration of the stay in intensive care unit was 3
days and themedian duration of artificial ventilationwas 16 h.
All except two infants were discharged on the 5th post-oper-
ative day. None had LV systolic dysfunction at discharge. Two
patients died during in-hospital stay from suspected ventric-
ular tachyarrhythmia and hospital-acquired, fulminant
bronchopneumonia leading to septicemia and multi-organ
failure, respectively.3.6. Complications
3.6.1. Deaths
Three patients died including two infants who died in the
hospital, post-procedurally. One infant, who died suddenly
during breast-feeding on 3rd post-procedural day, had docu-
mented hypokalemia (serumKþ: 2.8mEq/L), which could have
resulted in torsade de pointes and ventricular fibrillation.
Alternatively, aspiration during breast-feeding could have
been the cause. The defect size was 8.2 mm and 10mmdevice
was deployed. Echocardiography done during and after
resuscitation showed the device lying in-situ and thereby,
ruled out device-induced obstruction/leak. A neonate weigh-
ing 2.7 kg suffered from hospital-acquired fulminant bron-
chopneumonia on 3rd post-procedural day. Blood culture was
positive for Klebsiella. There was no echocardiographic
evidence of vegetation on the device. Anti-Klebsiella antibiotics
were started; device retrieval was not contemplated. The baby
eventually expired on 18th day due to septicemia and multi-
organ failure. Six months after the device closure, an infantdied of acute gastroenteritis complicated by severe dehydra-
tion leading to renal dysfunction.
3.6.2. Complete heart block and LVOT obstruction
Two patients developed complete heart block (CHB) following
device deployment. As a protocol, epicardial wires were left
in-situ for up to 1 week; post-procedurally, in all patients. One
patient with late (5th day) onset CHB regained sinus rhythm,
48 h later, on oral prednisolone (2 mg/kg/d), which was dis-
continued after 1 week. There was no evidence of any
conduction disturbance on Holter, 6 months later. Another
infant developed early onset (12 h after device deployment)
persistent CHB unresponsive to oral steroid therapy and
necessitating permanent pacemaker implantation. In
a 12mmmid-muscular defect, a 14mmdevice with 7mm rim
all around it was deployed. Since the heart block developed
post-procedurally, we did not retrieve the device. On echo-
cardiography undertaken at 18 months follow-up, she was
found to have developed LV outflow tract obstruction (peak
aortic velocity 4.1 m/sec). Inappropriately large-sized device
protruding into the outflow tract was surgically removed fol-
lowed by patch closure of the defect.
3.6.3. Esophageal tear
Esophageal tear resulted from the use of pediatric (instead of
neonatal) transesophageal probe in an infant weighing more
than 4 kg. The baby recovered completely with conservative
management.
3.7. Follow-up
All 22 infants, who went home, were asymptomatic at 1 and 3
months of follow-up. At 6 months, all drugs except aspirin
were stopped. On repeat echocardiography at 6 months, 8 out
of 10 infants with trivial residual shunt had no residual shunt.
Trivial shunt persisted in the remaining 2 infants. Six months
after the procedure, 1 infant died of severe gastroenteritis.
i n d i a n h e a r t j o u r n a l 6 4 ( 2 0 1 2 ) 5 5 9e5 6 7564One infant who developed intra-procedural heart block and
required permanent pacemaker prior to discharge presented
with device-related LV outflow tract obstruction at 18months.
The child underwent surgical device removal followed by
patch closure of the defect. After mean 26.23  6.63 mon, all
but two infants remained asymptomatic with adequate
weight gain and near complete regression of pulmonary
hypertension. Two infants required hospitalization for non-
cardiac illness.4. Discussion
Conventional surgical closure of VSD in small, low weight
infants is challenging. Kitagawa et al4 reported 10% rate of
reoperation for residual defects after surgical closure ofmVSD
in 22 infants using right atriotomy with or without left ven-
triculotomy approach. Wollenek et al reported similar reop-
eration rate after left ventriculotomy approach with mortality
rate as high as 16%.21 They concluded that pulmonary artery
banding is a better option for infantswith significantmVSD. In
another series of 130 patients (61 infants) with isolatedmVSD,
the post-surgical repair mortality was 7.7%.2 Stellin et al7
described surgical closure of apical VSD in four infants
through right apical ventriculotomy as a better approach.
However, it still required CPB and circulatory arrest. On the
other hand, retrospective analysis of surgical closure of iso-
lated VSDs by Scully et al has had excellent results with
extremely low incidence of adverse events.22
Initial intraoperative device closure procedures that
required both CPB and circulatory arrest, had high mortality
and failure rates ranging from 14 to 25%.23,24 Since the first
perventricular device closure of mVSD in animals, and later in
humans by Amin and colleagues,25e28 nearly 35 cases of per-
ventricular device closure of isolated mVSD in infants with
short-term follow-up have been reported in several small
series11e18,29 (Table 2). In a retrospective study, Bacha et al11
first reported, the safety and efficacy of perventricular device
closure in 6 children (20 dayse3 years; 3e20 kg). This study
was instrumental in establishing the feasibility of hybrid
procedure in infants and small children. Crossland et al
confirmed that perventricular device closure of isolated large
mVSD is safe and effective in 8 infants (median agee 14 (2e41)
weeks; median weight e 4 (3e6.6) kg) at short-term follow-
up.13 Gan et al reported similar results in 8 patients (mean age
2.5  3.6 years, mean weight of 10.9  7.6 kg) with post-
procedural hospital stay of 7.9  2.2 days.14 In their experi-
ence on mVSD device closure, Karim et al undertook
successful perventricular device closure in 8 out of 20
infants.15 Recently, Bendaly et al confirmed the feasibility of
perventricular device closure in 6 infants (median age 4.6
(1.7e24.6) months; median weight 5.7 (4e13) kg) and reaf-
firmed its safety at 2 years post-intervention.16
We have presented a single center prospective experience
on the feasibility and mid-term outcome of perventricular
device closure of isolated, large, mid-muscular VSD in a rela-
tively large cohort of high-risk, malnourished infants. Our
population is comparatively younger (mean age: 6.01  2.37
mon), with lower body weight (mean weight: 4.27  0.56 kg)
and sicker (PEM grade IIeIV in 80%) than that in the previouslypublished reports. In an analysis ofmore than 14,000 neonates
undergoing surgery for CHD, low body weight remained
a strong predictor of higher mortality.30 The multivariate
analysis confirmed that low body weight, longer CPB and
aortic cross-clamp times as well as longer duration of circu-
latory arrest were high-risk predictors of in-hospital
mortality. Lower body weight was associated with higher
hospital mortality in a meta-analysis of seven series.31 Risk
correlation of lower weight has similar implication during
percutaneous intervention, as well. Holzer et al concluded
that low body weight, at the time of procedure, significantly
correlates with an increased risk of procedure as well as
device-related complications ( p e 0.007). The median weight
of patients who had unsuccessful percutaneous procedures
was 6.5 kg as against 9.4 kg in the patients who had
a successful procedure.10 By virtue of their age, weight,
primary cardiac illness and nutritional status, our patients
were among the substantially high-risk candidates for
surgical as well as perventricular device closure.
Perventricular device closurewas deemed successful when
the occluder could be placed in the correct position, which
was possible in 21 of 24 patients (87.5%). None of our infants
required PA banding. Three patients required immediate
surgical intervention due to inability to advance the sheath
across the posterior muscular defect in one, LV perforation in
the other and presence of a large residual shunt in the third
that had a malaligned muscular defect. After this continuous
TEE-guided-experience in the operating room, it was consid-
ered prudent to have an additional imaging modality like
fluoroscopy to improve the efficacy and safety of perven-
tricular device closure of VSD. We also believe that certain
anatomical variants of muscular defects like high posterior
mVSD, distal apical mVSD and malaligned mVSD may not be
currently considered suitable for perventricular device closure
and necessitate the development of some specifically
designed hardware. Having been unable to cross high poste-
rior muscular VSD with conventional RV access, Bacha and
colleagues11 successfully closed it by switching over to pera-
trial approach in one of their patients. In a multicenter
retrospective analysis reported by Ina Michel-Behnke et al,
device placement was successful in 23 out of 26 (88.5%)
procedures including perventricular approach in 20. Device
removal was necessary in three due to arrhythmia, malposi-
tioning or additional defects.17
4.1. Complications
We observed certain avoidable complications like perioper-
ative CHB, late LVOTO, esophageal tear and infection. Some of
themwere due to very large defect requiring bulky device and
defects close to or extending into the inlet, posterior or apical
septum, which we may consider as not suitable for device
closure, as yet. Also we emphasize vigilant perioperative care
for the prevention of infection and arrhythmia and judicious
use of transesophageal probes by skilled and experienced
imaging expert to avoid potentially fatal esophageal tear.
After successful device closure, two infants died post-
procedurally, in-hospital, due to suspected ventricular
arrhythmia in one and septicemia leading to multi-organ
failure in the other. Two patients developed CHB after device
Table 2 e Clinical studies involving perventricular device closure of mVSDs.
Study Patients
(CPB required)
Age (mean) Weight (mean kg) Procedural difficulties
or complications
Add onal procedure/
outcome
Follow-up (months)
Bacha et al11,12 11 (9) 14 de3 yrs 3e20 Peratrial approach after
failed PV approach: 1
Difficult deployment of RV disc: 1
Mediasti s: 1 3e23 (12)
Crossland et al13 8 (1) 2e41 wks (14) 3e6.6 (4) Incomplete RV disc opening:
1 (device reposioning on CPB)
Mild resi l shunt
at device ge
0.5e66 (7.2 wks)
Gan et al14 8 (3) 0.5e11 yrs (2.5  3.6) 5.5e27.5 (10.9  7.6) Incomplete RV disc expansion:
1 (surgical patch closure)
e 6
Karim et al15 8 (4) 18 dayse4.9 mon 3.2e7.3 Transient EMD: 1
Device migration: 1
Wire perforation: 1
Mediasti s: 1 (died of
sepsis af 10 months)
0.4e6.8 yrs (3.8)
Bendaly et al16 6 (1) 1.7e24.6 mon (9.8  9.1) 4e13 (7.2  3.7) Device embolization: 1
(Surgical patch closure)
LV pseud eurysm:
1 (coil em lization)
39.8  25.2
Ina Michel-
Behnke et al17
17 (2) 0.8e60.1 mon 3.2e16 CPR, rescue CPB: 1
Device repositioning: 2
Device removal: 1
Pericardial effusion: 1
2 died, o ue to LV dysfunction
and anot with complex CHD
died of u own etiology
12 dayse47 mon
Present Study 24 (3) 6.01  2.37 mon 4.27  0.56 Patch closure: 3
CHB: 2, one transient,
one required pacemaker
Fulminant bronchopneumonia: 1
Esophageal perforation: 1
Fatal ventricular tachyarrhythmia: 1
Patient w pacemaker developed
significan VOT obstruction
after 18 m ths.
One died acute gastroenteritis
after 6 nths
26.2  6.6
Abbreviations: PV e perventricular; mVSD emuscular ventricular septal defect; RV e right ventricle; LV e left ventricle; LVOT e left ventricular flow tract; EMD e electromechanical dissociation;
CPR e cardiopulmonary resuscitation; CPB e cardiopulmonary bypass; CHD e congenital heart disease; CHB e complete heart block.
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device-induced trauma to the conduction system in an
infant with a large defect. Late onset CHB could have been due
to edema around the conduction system, which may result
from procedural manipulation and device homing. Although
the latter may be transient, oral steroid therapy may help it
recover. Conduction blocks are well-described complications
in transcatheter closure of perimembranous VSD (pmVSD) as
well as mVSD particularly in patients with low body weight.
Dragos et al has reported CHB requiring permanent pace-
maker in 22.2%. Late onset CHBwas a significant complication
in their population particularly in patients less than 10 kg or
those having a higher device:defect ratio.32 Holzer et al re-
ported arrhythmic events in 20% including conduction blocks
(RBBB) in 2.6%.31 Serraf et al reported 3% incidence of CHB in
130 children after surgical closure of isolated multiple
ventricular septal defects.2
Thoughnot observed in this series, other procedure-related
difficulties or complications associated with perventricular
device closure (Table 2) include, device embolization,16 LV
pseudoaneurysm,17 and unexpanded RV disc protruding into
pericardium.11,29 Incomplete RV disc expansion with screw or
disc protruding into the pericardium is the most common
another complication reported in literature11e14 however
sometimes can be avoided by selecting duct occluder.
As observed in our study, Bacha et al experienced similar
difficulty in crossing the posterior defect with conventional
RV access, but they closed the defect with peratrial tech-
nique.11 Another potential complication requiring immediate
surgical closure is device migration or embolization.14,17,18
Karim et al had guide wire perforation in one of their patient.
There are some uncommon but late complications include LV
pseudoaneurysm(possiblydue to sheathordilator-related free
wall injury),17 LVOTO due to disc protrusion etc. Air embolism,
hemolysis and tricuspid regurgitationmay occur, very rarely.
4.2. Hybrid intervention
After the initial experience in the operating theatre on 18
patients, we undertook mVSD device closure in the catheter-
ization laboratory with surgical preparedness in subsequent 6
infants. We observed that combined fluoroscopy and TEE
guidance significantly helped guide wire manipulation across
the mVSD, sheath advancement and device deployment as
compared to TEE guidance, alone. Hence a hybrid cardiac
catheterization lab within a surgical theatre would be an ideal
setup to perform such technically challenging procedures. A
hybrid technique does not require CPB or full sternotomy.
Other advantages include avoidance of transection of the
moderator band or other RV muscle bundles, immediate
confirmation of adequate closure, and avoidance of ventric-
ular incisions. Difficult deployment of RV disk in distal or
apical VSD can be dealt with by a simple pledgetted stitch
placed on the beating-heart or using the duct occluder until
custom-made device is available.14,15,18
With advent of hybrid technique the indications for
surgery are likely to be redefined in selected patients. It
appears that palliative PA banding may not be indicated any
more in infants with large muscular VSD. One-stage repair
can be offered to neonates with aortic coarctation andmuscular VSD. Similarly, large muscular VSD can be closed
using a perventricular technique at the time of PA band
takedown. In addition to the primary closure of muscular
VSDs,11e13 the perventricular technique appears to be excel-
lent for device closure of perimembranous VSD in the oper-
ating room, particularly in small babies, who are high-risk
candidates for closure in the catheterization laboratory.33,34
Limitation: our study involves prospectively followed
cohort of infants subjected to perventricular mVSD device
closure. There is no randomized comparison with surgical
closure arm. The duration of follow-up is medium term and
therefore this study is unable to address incidence of
ventricular arrhythmias, ventricular dysfunction, pseudoa-
neurysm and sudden deaths, which have been reported late
after surgical closure.5. Conclusion
In selected high-risk infants, perventricular device closure of
isolated mVSD is effective and may either substitute or
complement the conventional surgical closure depending on
the performance of institutional pediatric cardiac surgery
program. The procedural safety can certainly be improved
with more precautions for preventable complications. Until
specifically designed hardware is available, very large defect
or defects extending into inlet, posterior or apical septum are
not suitable for perventricular closure.Conflicts of interest
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